Barclays lowered the firm’s price target on Sarepta (SRPT) to $20 from $22 and keeps an Equal Weight rating on the shares following the Q3 report. Elevidys beat consensus estimates by a large margin and the company expects the demand to continue, the analyst tells investors in a research note. The firm calls the ESSENCE study failure “unfortunate,” but says both Amondys 45 and Vyondys 53 are unlikely to be pulled off the market. It views the stock pullback yesterday as overdone.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta upgraded to Outperform from Neutral at Mizuho
- Sarepta Therapeutics’ Earnings Call: Revenue Resilience Amid Challenges
- Mixed Financial Signals and Future Revenue Concerns Lead to Hold Rating for Sarepta Therapeutics
- Sarepta Stock’s (SRPT) Painful Plunge! Is There Any Hope Left for Investors after DMD Trial Miss?
- Midday Fly By: Palantir reports Q3 beat, Starbucks forms China JV